Longitudinal rotation: A new way to detect the cardiotoxicity of anthracycline-based chemotherapy in breast cancer patients

6Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

Background and aims: The study was to compare cardiac parameters before and after anthracycline-based chemotherapy and identify a parameter for detecting cardiotoxicity in breast cancer patients. Methods: Cardiac function in 43 female breast cancer patients was evaluated at three time points: baseline, 1-3 days before the initiation of anthracycline-based chemotherapy; 3 weeks and 6 months after the final cycle of chemotherapy. At each visit, the peak longitudinal velocity; strain rate; peak systolic strain; peak systolic longitudinal displacement, and segmental and global longitudinal rotation degrees of the left ventricular were measured. Results: The peak early-diastole left ventricular wall velocity at baseline was significantly higher than the values at 3 weeks and 6 months after the final cycle of chemotherapy. The absolute value of the lateral wall peak systolic longitudinal rotation degrees was significantly higher at baseline than at 3 weeks and 6 months after the final cycle of chemotherapy, whereas the absolute value of the global peak systolic longitudinal rotation degrees at baseline was significantly lower than the values at 3 weeks and 6 months after the final cycle of chemotherapy. None of the measured parameters differed significantly between the 3 weeks and 6 months after the final cycle of chemotherapy. Conclusions: Cardiac diastolic and systolic dysfunction was found after anthracycline-based chemotherapy in this study, and the peak systolic longitudinal rotation degrees can be used to detect dysfunction after chemotherapy. The cardiotoxicity of epirubicin-based chemotherapy is stronger than that of therarubicinbased chemotherapy.

Cite

CITATION STYLE

APA

Huang, J., Yan, Z. N., Rui, Y. F., Shen, D., Fan, L., & Chen, D. L. (2017). Longitudinal rotation: A new way to detect the cardiotoxicity of anthracycline-based chemotherapy in breast cancer patients. Oncotarget, 8(41), 70072–70083. https://doi.org/10.18632/oncotarget.19585

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free